Nexavar access scheme fails to sway NICE
This article was originally published in Scrip
Executive Summary
A new draft of guidance for the national health service in England and Wales comes to the same conclusion as an earlier version – that Bayer Schering Pharma's Nexavar (sorafenib) is not cost-effective in the treatment of advanced hepatocellular carcinoma.